Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Consensus Target Price of $110.91 According to Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been assigned a consensus rating of “Moderate Buy” from the fifteen research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eleven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $110.91.

A number of research analysts have commented on the stock. Citizens Jmp reissued a “market outperform” rating and set a $110.00 target price on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Weiss Ratings raised shares of Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a research note on Thursday. Wall Street Zen downgraded shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 3rd. Finally, Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a report on Friday, August 7th.

Hedge Funds Weigh In On Structure Therapeutics

Large investors have recently made changes to their positions in the business. Orbimed Advisors LLC grew its stake in shares of Structure Therapeutics by 27.0% during the 1st quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after acquiring an additional 313,600 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Structure Therapeutics by 5.2% in the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after buying an additional 264,833 shares during the last quarter. Siren L.L.C. boosted its position in Structure Therapeutics by 23.2% during the first quarter. Siren L.L.C. now owns 1,328,698 shares of the company’s stock worth $64,043,000 after purchasing an additional 250,000 shares during the period. SEB Asset Management AB bought a new position in Structure Therapeutics in the 1st quarter valued at about $11,811,000. Finally, Bank of America Corp DE boosted its stake in Structure Therapeutics by 617.0% in the 1st quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock valued at $10,948,000 after purchasing an additional 195,454 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Price Performance

Shares of GPCR traded up $0.16 during mid-day trading on Friday, reaching $20.00. 1,346,219 shares of the company’s stock traded hands, compared to its average volume of 985,796. The stock has a market cap of $1.39 billion, a P/E ratio of -15.50 and a beta of -1.12. The stock’s 50-day moving average is $27.88 and its two-hundred day moving average is $46.06. Structure Therapeutics has a 12 month low of $18.70 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). Research analysts predict that Structure Therapeutics will post -2.05 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.